Literature DB >> 30737824

Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.

Haijun Tian1, Tangjun Zhou1, Hongfang Chen1, Chenshuang Li2, Ziyue Jiang3, Lifeng Lao4, Suzana Assad Kahn5,6, Maria Eugenia Leite Duarte5, Jie Zhao1, Michael D Daubs7, Zorica Buser8, Elsa J Brochmann9,10,11, Jeffrey C Wang8, Samuel S Murray9,10,11.   

Abstract

The correlation between BMP-2 and osteosarcoma growth has gained increased interest in the recent years, however, there is still no consensus. In this study, we tested the effects of BMP-2 on osteosarcoma cells through both in vitro and in vivo experiments. The effect of BMP-2 on the proliferation, migration and invasion of osteosarcoma cells was tested in vitro. Subcutaneous and intratibial tumor models were used for the in vivo experiments in nude mice. The effects of BMP-2 on EMT of osteosarcoma cells and the Wnt/β-catenin signaling pathway were also tested using a variety of biochemical methods. In vitro tests did not show a significant effect of BMP-2 on tumor cell proliferation. However, BMP-2 increased the mobility of tumor cells and the invasion assay demonstrated that BMP-2 promoted invasion of osteosarcoma cells in vitro. In vivo animal study showed that BMP-2 dramatically enhanced tumor growth. We also found that BMP-2 induced EMT of osteosarcoma cells. The expression levels of Axin2 and Dkk-1 were both down regulated by BMP-2 treatment, while β-catenin, c-myc and Cyclin-D1 were all upregulated. The expression of Wnt3α and p-GSK-3β were also significantly upregulated indicating that the Wnt/β-catenin signaling pathway was activated during the EMT of osteosarcoma driven by BMP-2. From this study, we can conclude that BMP-2 significantly promotes growth of osteosarcoma cells (143B, MG63), and enhances mobility and invasiveness of tumor cells as demonstrated in vitro. The underlying mechanism might be that BMP-2 promotes EMT of osteosarcoma through the Wnt/β-catenin signaling pathway.
© 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1638-1648, 2019. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  Wnt/β-catenin; bone morphogenetic protein-2; epithelial-mesenchymal transition; osteosarcoma

Mesh:

Substances:

Year:  2019        PMID: 30737824     DOI: 10.1002/jor.24244

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  13 in total

Review 1.  Impact of Frontier Development of Alveolar Bone Grafting on Orthodontic Tooth Movement.

Authors:  Yilan Miao; Yu-Cheng Chang; Nipul Tanna; Nicolette Almer; Chun-Hsi Chung; Min Zou; Zhong Zheng; Chenshuang Li
Journal:  Front Bioeng Biotechnol       Date:  2022-06-30

2.  CORR Insights®: Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma?

Authors:  Terri A Zachos
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

3.  miR-548d-3p inhibits osteosarcoma by downregulating KRAS.

Authors:  Jianhua Chen; Chongnan Yan; Honghao Yu; Shihan Zhen; Quan Yuan
Journal:  Aging (Albany NY)       Date:  2019-07-21       Impact factor: 5.682

4.  High SENP3 Expression Promotes Cell Migration, Invasion, and Proliferation by Modulating DNA Methylation of E-Cadherin in Osteosarcoma.

Authors:  Pu Yang; Yan Liu; Yin Chao Qi; Zhang Hong Lian
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma.

Authors:  Yingying Miao; Guifeng Liu; Lin Liu
Journal:  Cancer Cell Int       Date:  2021-01-04       Impact factor: 5.722

Review 6.  Mechanisms, Diagnosis and Treatment of Bone Metastases.

Authors:  Jozef Ban; Valerie Fock; Dave N T Aryee; Heinrich Kovar
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

7.  Identification of abnormally high expression of POGZ as a new biomarker associated with a poor prognosis in osteosarcoma.

Authors:  Sikuan Zheng; Yue Liu; Haohe Sun; Jingyu Jia; Tianlong Wu; Rui Ding; Xigao Cheng
Journal:  Eur J Histochem       Date:  2021-09-03       Impact factor: 1.966

8.  ML264 inhibits osteosarcoma growth and metastasis via inhibition of JAK2/STAT3 and WNT/β-catenin signalling pathways.

Authors:  Hai Huang; Ying Han; Zhijun Chen; Xin Pan; Putao Yuan; Xiangde Zhao; Hongfang Zhu; Jiying Wang; Xuewu Sun; Peihua Shi
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

9.  High neural precursor cell-expressed developmentally down-regulated 9 expression is a poor prognostic indicator for osteosarcoma.

Authors:  Jinyi Feng; Yang Gu; Linquan Zhou; Gang Rui; Wenge Liu
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.